Apomorphine sublingual - Amarin Corporation

Drug Profile

Apomorphine sublingual - Amarin Corporation

Alternative Names: Apomorphine oral

Latest Information Update: 19 Apr 2011

Price : $50

At a glance

  • Originator
  • Developer Amarin Corporation
  • Class Analgesics; Antiparkinsonians; Aporphines; Erectile dysfunction therapies; Small molecules
  • Mechanism of Action Dopamine D2 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Parkinson's disease

Most Recent Events

  • 19 Feb 2009 No development reported - Phase-I for Parkinson's disease in United Kingdom (Sublingual)
  • 25 Sep 2008 Apomorphine sublingual is available for licensing (http://www.amarincorp.com)
  • 13 Aug 2007 Amarin Corporation completes a phase I trial in healthy volunteers
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top